Kim 2004.

Methods	Design: randomised, placebo‐controlled, parallel‐group trial
Participants	Number assigned: 129 adults and elderly (macrolide n = 64, placebo n = 65) Age in years (mean ± SD): macrolide: 60.0 ± 10.0, placebo: 59.6 ± 10.1 Setting: secondary care
Interventions	Indication: acute coronary syndrome who underwent PCI Type of macrolide: azithromycin Route: per oral Dose: 500 mg daily for 3 days before and after PCI, followed by 500 mg/week Duration of treatment: 3 weeks Total treatment dose: 4000 mg
Outcomes	Adverse events stated as an outcome in trial registration/protocol/paper: unclear Adverse events ascertainment: clinical examination (lab tests) Adverse events: incomplete reporting, author contacted Antimicrobial resistance: not reported Death: data reported
Funding sources	Not stated
Notes	Concomitant medication: yes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Sequence generation not described.
Allocation concealment (selection bias)	Unclear risk	Allocation not described.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Unclear if matching placebo used.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	No adverse events reported, death is an objective outcome.
Incomplete outcome data (attrition bias) All outcomes	Low risk	12 months follow‐up in 95% of participants.
Selective reporting (reporting bias)	High risk	Adverse events not stated clearly as an outcome, unclear ascertainment, adverse events not reported (only adverse cardiac outcomes are reported on).
Other bias	Low risk	None were identified.